Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Status: Recruiting
Location: See all (77) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
• Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
Locations
United States
Arizona
Local Institution - 0005
WITHDRAWN
Phoenix
California
Local Institution - 0016
NOT_YET_RECRUITING
Bellflower
Local Institution - 0082
NOT_YET_RECRUITING
Long Beach
Delaware
Local Institution - 0003
WITHDRAWN
Newark
Florida
Local Institution - 0001
NOT_YET_RECRUITING
St. Petersburg
Illinois
Local Institution - 0064
NOT_YET_RECRUITING
Chicago
Kansas
Local Institution - 0112
NOT_YET_RECRUITING
Wichita
Massachusetts
Local Institution - 0080
NOT_YET_RECRUITING
Boston
Local Institution - 0092
NOT_YET_RECRUITING
Boston
Minnesota
Mayo Clinic in Rochester, Minnesota
RECRUITING
Rochester
Local Institution - 0073
NOT_YET_RECRUITING
Saint Paul
Nebraska
Local Institution - 0036
NOT_YET_RECRUITING
Omaha
New York
Local Institution - 0116
NOT_YET_RECRUITING
New York
Oregon
Local Institution - 0004
NOT_YET_RECRUITING
Eugene
Tennessee
Local Institution - 0023
NOT_YET_RECRUITING
Germantown
Texas
Local Institution - 0002
NOT_YET_RECRUITING
Grapevine
Washington
Local Institution - 0013
NOT_YET_RECRUITING
Bellingham
Other Locations
Australia
Local Institution - 0093
NOT_YET_RECRUITING
St Leonards
Belgium
Local Institution - 0033
NOT_YET_RECRUITING
Ghent
Canada
Local Institution - 0072
NOT_YET_RECRUITING
Vancouver
France
Local Institution - 0032
NOT_YET_RECRUITING
Angers
Local Institution - 0091
NOT_YET_RECRUITING
Besançon
Local Institution - 0090
NOT_YET_RECRUITING
Bron
Local Institution - 0085
NOT_YET_RECRUITING
Créteil
Local Institution - 0075
NOT_YET_RECRUITING
Gleizé
Local Institution - 0065
NOT_YET_RECRUITING
Grenoble
Local Institution - 0059
NOT_YET_RECRUITING
Marseille
Local Institution - 0076
NOT_YET_RECRUITING
Nice
Local Institution - 0086
NOT_YET_RECRUITING
Nice
Local Institution - 0061
NOT_YET_RECRUITING
Paris
Local Institution - 0103
NOT_YET_RECRUITING
Pessac
Local Institution - 0051
NOT_YET_RECRUITING
Poitiers
Local Institution - 0058
NOT_YET_RECRUITING
Quimper
Local Institution - 0050
NOT_YET_RECRUITING
Saint-herblain
Local Institution - 0063
NOT_YET_RECRUITING
Saint-herblain
Local Institution - 0078
NOT_YET_RECRUITING
Saint-mandé
Local Institution - 0074
NOT_YET_RECRUITING
Strasbourg
Local Institution - 0077
NOT_YET_RECRUITING
Tours
Germany
Local Institution - 0012
NOT_YET_RECRUITING
München
Greece
Local Institution - 0081
NOT_YET_RECRUITING
Athens
Local Institution - 0022
NOT_YET_RECRUITING
Attiki
Local Institution - 0087
NOT_YET_RECRUITING
Thessaloniki
Israel
Local Institution - 0055
NOT_YET_RECRUITING
Jerusalem
Local Institution - 0057
NOT_YET_RECRUITING
Tel Aviv
Local Institution - 0106
NOT_YET_RECRUITING
Tel Aviv
Italy
Local Institution - 0053
NOT_YET_RECRUITING
Bologna
Local Institution - 0054
NOT_YET_RECRUITING
Florence
Local Institution - 0052
NOT_YET_RECRUITING
Meldola
Local Institution - 0021
NOT_YET_RECRUITING
Milan
Local Institution - 0107
NOT_YET_RECRUITING
Milan
Local Institution - 0020
NOT_YET_RECRUITING
Orbassano
Local Institution - 0079
NOT_YET_RECRUITING
Pesaro
Local Institution - 0031
NOT_YET_RECRUITING
Roma
Local Institution - 0019
NOT_YET_RECRUITING
Rome
Local Institution - 0026
NOT_YET_RECRUITING
Terni (perugia)
Netherlands
Local Institution - 0034
NOT_YET_RECRUITING
Amsterdam
Local Institution - 0056
NOT_YET_RECRUITING
Breda
Local Institution - 0035
NOT_YET_RECRUITING
Harderwijk
Local Institution - 0071
NOT_YET_RECRUITING
Utrecht
Portugal
Local Institution - 0014
NOT_YET_RECRUITING
Lisbon
Romania
Local Institution - 0060
NOT_YET_RECRUITING
Craiova
Singapore
Local Institution - 0088
NOT_YET_RECRUITING
Singapore
Spain
Local Institution - 0007
NOT_YET_RECRUITING
A Coruña
Local Institution - 0006
NOT_YET_RECRUITING
Badalona
Local Institution - 0010
NOT_YET_RECRUITING
Barcelona
Local Institution - 0029
NOT_YET_RECRUITING
Barcelona
Local Institution - 0027
NOT_YET_RECRUITING
Córdoba
Local Institution - 0015
NOT_YET_RECRUITING
Madrid
Local Institution - 0024
NOT_YET_RECRUITING
Madrid
Local Institution - 0062
NOT_YET_RECRUITING
Madrid
Local Institution - 0083
NOT_YET_RECRUITING
Madrid
Local Institution - 0018
NOT_YET_RECRUITING
Málaga
Local Institution - 0011
NOT_YET_RECRUITING
Palma
Local Institution - 0009
NOT_YET_RECRUITING
Pamplona
Local Institution - 0030
NOT_YET_RECRUITING
Santander
Local Institution - 0008
NOT_YET_RECRUITING
Seville
Local Institution - 0084
NOT_YET_RECRUITING
Valencia
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2026-05-06
Estimated Completion Date: 2028-02-16
Participants
Target number of participants: 170
Treatments
Experimental: Arm A1
Experimental: Arm A2
Experimental: Arm B1
Experimental: Arm B2
Experimental: Arm B3
Experimental: Arm B4
Experimental: Arm C1
Experimental: Arm C2
Experimental: Arm C3
Experimental: Arm C4
Related Therapeutic Areas
Sponsors
Leads: Mirati Therapeutics Inc.